Business Wire

CA-DENODO

2.6.2024 14:31:32 CEST | Business Wire | Press release

Share
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises

Denodo, a leader in data management, announced that it has integrated NVIDIA NIM inference microservices into the Denodo Platform, as part of its focus on bolstering its rapidly expanding artificial intelligence (AI) capabilities.

The Denodo Platform's logical data management capabilities, combined with NVIDIA NIM, enable enterprise customers to:

  • Rapidly curate and transform data into AI-ready pipelines to feed large language models (LLMs)
  • Improve model accuracy and combat hallucinations by accessing trusted enterprise data through retrieval augmented generation (RAG) pipelines.
  • Simplify secure, real-time access to distributed enterprise knowledge for generative AI applications
  • Maintain data privacy/security and enforce granular access controls for AI models that access organizational data
  • Fast-track AI/ML deployments from data prep to model scoring with NVIDIA NeMo, leveraging an integrated data fabric for enterprise data input into this process

NVIDIA NIM is a collection of cloud-native microservices that simplify and accelerate the deployment of generative AI models across a variety of environments, including the cloud, on-premises data centers, and workstations. It connects the power of the latest foundational AI models, securely deployed on NVIDIA’s accelerated infrastructure, with enterprise customers everywhere.

The Denodo Platform’s integration of NVIDIA NIM helps customers seamlessly leverage advanced AI capabilities within their data management workflows. It also helps enable enterprises to deploy and scale generative AI applications with unprecedented speed and efficiency. Key use cases include improved analytics and robust AI-driven insights across such verticals as financial services, healthcare, retail, and manufacturing, accelerating time to insight from diverse data sources. As an NVIDIA Metropolis partner, Denodo is working to deploy vision AI and vision language model (VLM) NIM microservices to streamline industrial processes and increase worker safety.

Using the Denodo Platform with NVIDIA NeMo can significantly boost SQL query generation accuracy for LLMs. RAG capabilities enable more trustworthy responses by enabling models to retrieve relevant knowledge from the data fabric before generating output, and the Denodo Platform helps to simplify and accelerate data access, while reducing errors, when models query the platform.

By integrating NVIDIA NIM, Denodo helps ensure that customers will be able to maintain full control over their AI deployments, whether on premises or in the cloud. The integration is set to deliver significant business benefits, including accelerated time to value and enhanced security for AI applications.

“I am thrilled by this integration, and I think it's a sign of the direction in which Denodo's logical data management capabilities can take us,” said Narayan Sundar, Senior Director-Strategic Alliances at Denodo. “Denodo is at the forefront of supporting RAG-enabled GenAI applications with real-time, governed, trusted data from an organization’s vast data estates, and I look forward to seeing the innovations, as they start to emerge, from enterprise customers that leverage the Denodo Platform with NVIDIA NIM integration.”

Learn more about the Denodo Platform with NVIDIA NIM integration.

About Denodo

Denodo is a leader in data management. The award-winning Denodo Platform is the leading logical data management platform for delivering data in the language of business, at the speed of business, for all data-related initiatives across the organization. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across enterprises in 30+ industries all over the world have received payback in less than six months. For more information, visit denodo.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240602559183/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye